- 1
Ardelyx, the biopharmaceutical company, released a Q1 report outperforming estimates. - 2
ARDX stock is performing well, gaining over 75% in 2023.
Ardelyx (NASDAQ: ARDX), the biopharmaceutical company beating expectations, posted a revenue of $11.37 Million in Q1 2023 reports. Contrary to the Zack Consensus Estimate of a loss of $0.11. The biopharmaceutical company founded in 2007, with headquarters in Waltham, MA, came out with a quarterly loss of $0.13 per share. This loss was $0.21 per share last year.
Ardelyx Inc. – The Biopharmaceutical Company Beating Expectations
The quarterly report, which came out on May 3, 2023, reported an …
Source: https://www.thecoinrepublic.com/2023/05/07/ardelyx-inc-nasdaq-ardx-can-it-continue-to-outdo-estimates/